Alkermes plc Q3 2026 Earnings Call Summary
Alkermes reported Q3 2026 earnings, highlighting 31% year-over-year growth in proprietary product sales, with 2026 sales expected to reach $1.6 billion. The company is expanding its orexin portfolio into ADHD and MDD, with six major clinical readouts anticipated in 2027. LUMRYZ's market access expanded to 80% of covered lives, and management expects net sales acceleration in 2027. The company maintains a strong financial position with $787 million in cash and investments.
How this was made

The 30-second read
Why it matters
The most tradable elements are the quantified commercial assumptions (2026 proprietary sales growth, LYBALVI access and 2027 gross-to-net range) and the stated 2027 clinical readout slate plus contingent launch timing for LUMRYZ in IH.
Market read
Traders can reassess Alkermes’ 2027 catalyst probability-weighting and commercial ramp expectations based on the call’s quantified assumptions and stated clinical readout schedule.
What to watch
Gross-to-net settling and COGS normalization are model assumptions; near-term margin and inventory dynamics (LUMRYZ inventory drawdown/build) could create volatility around quarterly reporting.
Background
This is a summary of Alkermes’ Q3 2026 earnings call, emphasizing strategy, commercial performance, and a 2027 orexin-focused clinical catalyst plan.
Ticker impact
Alkermes’ Q3 call outlines 2027 orexin pipeline readouts, LUMRYZ/LYBALVI commercial targets, and updated COGS normalization assumptions tied to the Avadel acquisition.
Likely upward bias as investors price in a data-rich 2027 calendar and clearer commercialization trajectory for LUMRYZ and LYBALVI.
The article provides forward-looking, decision-relevant specifics (2027 readouts count, gross-to-net range, launch contingency timing, and COGS normalization) that can re-rate expectations even without a new earnings print.
Market effects
Reinforces competitive framing in orexin agonists versus antagonists and oxybate, potentially affecting sentiment across CNS/psychiatry drug developers.
Limited direct regional spillover; primarily US biotech/CNS investor positioning.
Moderate, as orexin competition and clinical timelines are globally relevant for CNS investors, but the disclosure is company-specific.
Counterpoint
The call’s optimism depends on multiple clinical readouts and regulatory steps; investors may discount the 2027 calendar if trial outcomes or sNDA timing slip.
Key entities
- companyAlkermes plc
Subject of the earnings call summary, discussing orexin portfolio expansion, 2027 clinical catalysts, and 2027 financial modeling assumptions.
- productLUMRYZ
Orexin-related therapy discussed for potential IH launch timing contingent on sNDA after Phase 3 REVITALIZE data.
- productLYBALVI
Antipsychotic franchise discussed with expanded market access and a 2027 gross-to-net adjustment target.
- productVIVITROL
Alcohol dependence product referenced for gross-to-net and inventory favorability impacts in Q3.
- productARISTADA
Alcohol dependence product referenced for gross-to-net and inventory favorability impacts in Q3.


